It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Objective: Promptly treated erythema migrans (EM) has good prognosis. However, some patients report persistent symptoms. Do patients with EM have more symptoms than the general population? We describe individual symptoms and general function in EM-patients at time of diagnosis and one year after treatment.
Design: Prospective study with 1-year follow up after treatment. Questionnaires included a modified version of the Subjective Health Complaints Inventory, comprising three additional Lyme borreliosis (LB) related symptoms. General function was assessed using a five-point scale modified from the COOP/WONCA charts.
Setting: Norwegian general practice.
Subjects: A total of 188 patients were included in a randomized controlled trial comparing three antibiotic regimens for EM, of whom 139 had complete data for this study.
Main outcome measures: Individual symptoms, symptom load and general function.
Results: Mild symptoms were common, reported by 84.9% at baseline and by 85.6% at follow-up. At baseline, patients reported a mean of 5.4 symptoms, compared with 6.2 after one year. Severely bothersome symptoms and severely impaired general function were rare. Tiredness was the most reported symptom both at baseline and at follow-up. Palsy (other than facial) was the least reported symptom, but the only one with a significant increase. However, this was not associated to the EM.
Conclusion: The symptom load was comparable to that reported in the general population. We found an increase in symptom load at follow-up that did not significantly affect general function.
Implication: Monitoring patients’ symptom loads prior to treatment reduce the probability of attributing follow-up symptoms to LB.
- Key points
Erythema migrans has a good prognosis.Patients treated for erythema migrans have a slight increase in symptom load one year after treatment.
This increase does not affect general function.
The levels of subjective health complaints in patients treated for erythema migrans are comparable to the background population.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of General Practice, Norwegian Antibiotic Centre for Primary Care, University of Oslo, Oslo, Norway;
2 Department of Microbiology, Førde General Hospital, Førde Health Trust, Førde, Norway;
3 Norwegian National Advisory Unit on Tick-borne Diseases, Sørlandet Hospital, Arendal, Norway;
4 Department of General Practice, Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway